Dariohealth Stock Earnings Reports

Key points for investors: DarioHealth reported sequential revenue growth for a second consecutive quarter (Q1 2026 revenue $5.6M) while materially reducing operating expenses. The company is scaling its channel-led distribution: a newly contracting channel partner (from a large Northeastern hospital network) would add ~65 million covered lives and ~3,500 employer relationships, bringing total reach to ~175 million covered lives. Commercial momentum includes 10 new Q1 accounts, a $127M pipeline across 241 opportunities, and roughly $30M of contracted / late-stage ARR from 2025 signings expected to contribute revenue primarily in H2 2026 and into 2027. Dario is moving the platform closer to direct care (partnering with provider/care-delivery organizations rather than building full clinical capabilities internally) to access claims- and outcomes-based revenue; notable partnerships include deeper integration with GreenKey Health for a national obstructive sleep apnea pathway. Technology and data remain core advantages: Dario owns hardware and a proprietary data set (13+ billion real-world data points) powering DarioIQ; early DarioIQ results show up to +40% member retention and up to +55% active session lift versus control. Financially, Q1 gross margin was ~57% (B2B2C non-GAAP gross margin ~80% sustained), total OpEx down 21% YoY, non-GAAP operating loss improving, net cash used in operations $6M in Q1, and cash/short-term deposits $20M as of March. The company reiterated an active strategic review process (Perella Weinberg Partners / special committee) exploring strategic alternatives. Overall: commercialization is shifting from selling single accounts to scalable partner-led distribution, large 2025 contracts are moving into implementation (expected revenue recognition in H2), and the company is expanding into provider-enabled care pathways to capture larger healthcare spend while leveraging its AI/data moat to improve outcomes and engagement.